

---

## CONTENTS

---

### IMPORTANT NOTICE TO INVESTORS

*This prospectus is issued by our Company solely for the Public Offer and the Offer Shares and does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the Offer Shares. This prospectus may not be used for the purpose of, and does not constitute, an offer to sell or a solicitation of an offer to buy in any other jurisdiction or in any other circumstances. No action has been taken to permit a public offering of the Offer Shares or the distribution of this prospectus in any jurisdiction outside Hong Kong. The distribution of this prospectus and the offering and sale of the Offer Shares in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.*

*You should rely only on the information contained in this prospectus and the Application Forms to make your investment decision. We have not authorized anyone to provide you with information that is different from the information contained in this prospectus. Any information or representation not included in this prospectus must not be relied on by you as having been authorized by us, the Sole Sponsor, the Sole Bookrunner, the Underwriters, any of our or their respective directors, officers, employees, agents, affiliates or advisors or any other party involved in the Public Offer.*

	<u>Page</u>
Expected Timetable . . . . .	i
Contents . . . . .	iv
Summary . . . . .	1
Definitions . . . . .	20
Glossary of Technical Terms . . . . .	32
Forward-Looking Statements . . . . .	36
Risk Factors . . . . .	37
Waiver from Compliance with the Listing Rules . . . . .	63
Jacobson Pharma Distribution and the Spin-off . . . . .	64
Information About This Prospectus and the Public Offer . . . . .	70
Directors and Parties Involved in the Public Offer . . . . .	73
Corporate Information . . . . .	77
Industry Overview . . . . .	79
Regulatory Overview . . . . .	91
History, Reorganization and Corporate Structure . . . . .	107
Business . . . . .	120
Relationship with Jacobson Pharma . . . . .	185
Connected Transactions . . . . .	195
Directors and Senior Management . . . . .	203
Substantial Shareholders . . . . .	216
Share Capital . . . . .	217
Financial Information . . . . .	220

---

## CONTENTS

---

	<u>Page</u>
Future Plans and Use of Proceeds .....	272
Underwriting .....	273
Structure of the Public Offer .....	285
How to Apply for the Offer Shares .....	288
Appendix I — Accountants' Report .....	I-1
Appendix II — Unaudited Pro Forma Financial Information .....	II-1
Appendix III — Summary of the Constitution of the Company and Cayman Islands Company Law .....	III-1
Appendix IV — Statutory and General Information .....	IV-1
Appendix V — Documents Delivered to the Registrar of Companies and Available for Inspection .....	V-1